[Skip to Content]
[Skip to Content Landing]
Article
March 27, 1991

Sandoz and the Monitoring of Patients Receiving Clozapine-Reply

Author Affiliations

Sandoz Pharmaceuticals Corp East Hanover, NJ

Sandoz Pharmaceuticals Corp East Hanover, NJ

JAMA. 1991;265(12):1529. doi:10.1001/jama.1991.03460120042030

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.

Abstract

In Reply. —  We appreciate Dr Benton's incisive letter, and we agree fully with his ultimate conclusion: Sandoz would like to rid itself of this controversy. But even more important, we would like to see clozapine reach more of the severely ill schizophrenics who have had no significant relief from crippling symptoms when treated with old-fashioned neuroleptic drugs. In recent months, we have done much to achieve both of those goals, while ensuring that the breakthrough of clozapine therapy remains available to the patients who so desperately need it, despite potentially fatal adverse reactions.In December, we announced our intention to separate the monitoring of clozapine from sales of the drug itself. On January 14, we announced a new wholesale pricing policy for clozapine tablets to make certain that physicians, providers, funders, and patients understand that separation. We are engaged in discussions with providers and funders on criteria to determine

×